US 11,786,522 B2
Aripiprazole injectable suspension formulation having prolonged shelf life
Yunzhe Sun, Nanjing (CN); Qi Peng, Nanjing (CN); Cheng-Gang Lin, Nanjing (CN); Li Gui, Nanjing (CN); Zhihui Liu, Nanjing (CN); and Fei Liu, Nanjing (CN)
Assigned to Nanjing Noratech Pharmaceuticals Co., LTD, Nanjing (CN)
Appl. No. 15/755,801
Filed by Nanjing Noratech Pharmaceuticals Co., Ltd, Nanjing (CN)
PCT Filed Mar. 16, 2016, PCT No. PCT/CN2016/076454
§ 371(c)(1), (2) Date Feb. 27, 2018,
PCT Pub. No. WO2017/036118, PCT Pub. Date Mar. 9, 2017.
Claims priority of application No. 201510546844.0 (CN), filed on Aug. 31, 2015.
Prior Publication US 2019/0070171 A1, Mar. 7, 2019
Int. Cl. A61K 31/496 (2006.01); A61K 9/10 (2006.01); A61K 47/38 (2006.01); A61P 25/18 (2006.01); A61K 9/00 (2006.01); A61K 47/26 (2006.01)
CPC A61K 31/496 (2013.01) [A61K 9/0019 (2013.01); A61K 9/10 (2013.01); A61K 47/26 (2013.01); A61K 47/38 (2013.01); A61P 25/18 (2018.01)] 4 Claims
 
1. An aripiprazole injectable suspension formulation having prolonged shelf life, comprising aripiprazole in an amount of 200 mg/mL;
sodium carboxymethyl cellulose in an amount selected from 4 mg/mL or 8 mg/mL;
mannitol in an amount of 40 mg/mL;
polyoxyethylene (20) sorbitan monooleate in an amount selected from 4 mg/mL, 8 mg/mL or 24 mg/mL; and
sodium dihydrogen phosphate in an amount of 0.6 mg/mL.